Lingyi Bio Achieves Milestone with First Dose of LY-M003 Injection in Gene Therapy Clinical Trial for Wilson's Disease
On September 30, 2024, Lingyi (Hangzhou) Biotechnology Co., Ltd. (hereinafter referred to as "Lingyi Biotech") announced that its independently developed LY-M003 injection has successfully administered the first dose to a subject, marking a new hope for the treatment of Wilson's disease. This clinical study, titled "A Prospective, Single-Center, Open-Label, Single-Arm, Single-Dose Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LY-M003 Injection in Adult Patients with Wilson's Disease," is being conducted smoothly at The First Affiliated Hospital of Zhejiang University School of Medicine (hereinafter referred to as "Zhejiang Medical First Hospital"), initiated by Professor Yu Chaohui as the principal investigator.
Professor Yu Chaohui stated: "The successful administration of LY-M003 injection marks a significant breakthrough in the field of gene therapy. The patient has remained stable after administration, with no significant adverse reactions observed. We look forward to observing more data on the safety and efficacy of LY-M003 injection, bringing a breakthrough treatment option for patients with Wilson's disease." Professor Yu, the Vice President of Zhejiang Medical First Hospital and the leader of the Department of Gastroenterology, is a Professor of Internal Medicine, Chief Physician, and Doctoral Supervisor at Zhejiang University. He has long been engaged in the diagnosis and treatment of digestive system diseases, clinical teaching, and scientific research, and is committed to the mechanism research and new drug development for metabolic liver diseases.
Dr. Lin Qing, the founder and CEO of Lingyi Biotech, expressed: "We are very pleased to have the opportunity to collaborate with Professor Yu's team on the clinical study of LY-M003 injection for Wilson's disease. The initiation of this clinical study and the smooth administration of the first patient mark an important milestone in the development journey of Lingyi Biotech. We firmly believe that through unremitting efforts and continuous innovation, Lingyi Biotech will bring safe and long-term effective treatment drugs to patients with Wilson's disease."
Lingyi Biotech is committed to working hand in hand with colleagues in the global medical community to accelerate the clinical research and product development of LY-M003 injection, with the aim of bringing this innovative drug to patients with Wilson's disease worldwide as soon as possible, achieving the treatment vision of "one-time dosing, lifelong benefits.
